Trials / Unknown
UnknownNCT04623320
Validation of a 13C Glucose Breath Test Compared With the Euglycaemic Clamp Test
Validation of a 13C Glucose Breath Test to Quantify Insulin Resistance in Type 1 Diabetes Mellitus Compared With the Euglycaemic Clamp Test
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 50 (estimated)
- Sponsor
- University Hospital, Antwerp · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Insulin resistance can be assessed by the euglycaemic clamp technique. To date, this is the golden standard, but it is not suited for clinical practice. A 13C glucose breath test will be tested as a valid alternative. The curve of the exhaled 13C CO2 as a function of glucose metabolism can be correlated to the curve of the glucose disposal rate obtained via the clamp technique.
Detailed description
The hyperinsulinemic-euglycemic clamp technique is the golden standard to assess insulin resistance in type 1 diabetes subjects. The plasma insulin concentration is acutely raised and maintained at 100 μU/ml by a continuous infusion of insulin. Meanwhile, the plasma glucose concentration is held constant at basal levels by a variable glucose infusion. When the steady-state is achieved, the glucose infusion rate equals glucose uptake by all the tissues in the body and is therefore a measure of tissue insulin sensitivity. These data will be compared with the results of a 13C glucose breath test. Breath tests using 13C substrates are based on the principle that 13C CO2 in the exhaled breath can be measured as a metabolic tracer. Breath testing has a major advantage over the clamp test in that it can be performed non-invasively and repeatedly without necessary supervision by medical staff.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | euglycaemic clamp test | clamp test (golden standard) to determine insulin resistance |
| DIAGNOSTIC_TEST | 13C glucose breath test | 13C glucose breath test to compare with the golden standard |
Timeline
- Start date
- 2020-10-27
- Primary completion
- 2022-12-30
- Completion
- 2023-03-31
- First posted
- 2020-11-10
- Last updated
- 2022-03-18
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT04623320. Inclusion in this directory is not an endorsement.